The study, which focuses on the use of RP1 monotherapy for skin cancer treatment in transplant patients, was detailed at the AACR 2024 Annual Meeting.

The three-year outcomes from a Phase 1 study of a personalized mRNA cancer vaccine, autogene cevumeran (BNT122, RO7198457), have demonstrated sustained polyspecific T cell reactions and a reduction in tumor recurrence in patients.

Regeneron Pharmaceuticals has reported encouraging results from their Phase 1/2 clinical trial of linvoseltamab.

Vincerx Pharma, a biopharmaceutical firm, has reported encouraging preliminary results from the Phase 1 clinical trial of its drug candidate VIP236, which targets metastatic solid tumors.

May 16th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Clover Biopharmaceuticals, a leading biotech firm, has reported promising initial results from its Phase I clinical trial for SCB-1019, a novel bivalent RSV vaccine.

Inozyme Pharma, Inc. recently reported promising data from Phase 1/2 clinical trials of their drug INZ-701.

Cynata Therapeutics has successfully completed patient recruitment for its Phase 1 clinical trial of CYP-006TK, a treatment for diabetic foot ulcers (DFU).

The trial focused on MT-601, a novel T cell therapy targeting various tumor antigens, and was well-tolerated by participants, leading to sustained objective responses.

CytomX Therapeutics has initiated a Phase 1 clinical trial for CX-2051, an antibody drug conjugate (ADC) aimed at treating advanced solid tumors.

Oryzon Genomics, a biopharmaceutical firm specializing in epigenetic therapies for diseases with significant medical needs, has received approval from the U.S. FDA to begin a Phase I/II clinical trial.

Encouraging initial findings indicate that individuals with relapsed or refractory multiple myeloma, who experienced progression post BCMA-directed treatments, have shown clinical improvements with P-BCMA-ALLO1, demonstrating a good safety profile.